805250-17-3

Basic information

• Product Name: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester
• Synonyms: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester;SR03298A;Methyl 2-(5-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate;METHYL 2-(6-HYDROXY-2,3-DIHYDROBENZOFURAN-3-YL)ACETATE;-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester;(6-Hydroxy-2,3-dihydrobenzofuran-3-yl)acetic acid methyl ester;Methyl (6-hydroxy-2,3-dihydro-1-benzofuran-3-yl)acetate;Methyl 6-Hydroxy-2,3-dihydrobenzofuran-3-ylacetate
• CAS NO: 805250-17-3
• Molecular Formula: C₁₁H₁₂O₄
• Molecular Weight: 208.21058
• Mol File: 805250-17-3.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 326.5±42.0℃ (760 Torr)
• Flash Point: 126.9±21.4℃
• Appearance: /
• Density: 1.257±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.77±0.40(Predicted)
• CAS DataBase Reference: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(805250-17-3)
• EPA Substance Registry System: 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester(805250-17-3)

Safety Data

• Hazardous Substances Data: 805250-17-3(Hazardous Substances Data)

Usage

Description

3-Benzofuranacetic acid, 2,3-dihydro-6-hydroxy-, Methyl ester is an organic compound that serves as an intermediate in the synthesis of pharmaceuticals. It is characterized by its benzofuran core structure, which is fused to a six-membered oxygen-containing ring, and a carboxylic acid group that is esterified with a methyl group. 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester is known for its potential role in the development of medications for diabetes management.

Uses

Used in Pharmaceutical Industry:
3-Benzofuranacetic acid, 2,3-dihydro-6-hydroxy-, Methyl ester is used as a synthetic intermediate for the development of novel oral medications, specifically for TAK-875 (T004915). 3-Benzofuranaceticacid,2,3-dihydro-6-hydroxy-,Methylester plays a crucial role in the synthesis of a medication designed to enhance insulin secretion in a glucose-dependent manner, which can potentially improve blood sugar control without the risk of hypoglycemia. This application is particularly relevant for the management of diabetes and related metabolic disorders, offering a promising avenue for the development of safer and more effective treatments.

Upstream product

• 93772-88-4 6-methoxy-3-methoxycarbonylmethyl-2,3-dihydrobenzofuran 
• 67-56-1 methanol 
• 1000414-37-8 2-(6-hydroxy-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 69716-04-7 2-(6-hydroxy-1-benzofuran-3-yl)acetic acid 
• 108-46-3 recorcinol 
• 25392-41-0 4-chloromethyl-7-hydroxycoumarin 
• 726174-52-3 (6-hydroxy-benzofuran-3-yl)-acetic acid methyl ester 

Downstream Products

• 1356599-30-8 {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetic acid 
• 1356600-64-0 methyl {6-[(4-{[(2Z)-2-(methoxyimino)-2-phenylethyl]oxy}benzyl)oxy]-2,3-dihydro-benzofuran-3-yl}acetate 
• 805248-74-2 methyl 2-[6-((2',4'-dimethylbiphenyl-3-yl)methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetate 
• 805248-75-3 2-[6-[(2',4'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid 
• 805248-71-9 {6-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 
• 1350080-99-7 methyl {6-[(6-methoxy-2',6'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetate 
• 1347943-50-3 {6-[(6-methoxy-2',6'-dimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 
• 1359669-71-8 methyl (6-{[6-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 805248-76-4 methyl 2-{6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetate 
• 805248-77-5 {6-[(2',4',6'-trimethylbiphenyl-3-yl)methoxy]-2,3-dihydro-1-benzofuran-3-yl}acetic acid 
• 805249-07-4 methyl (6-{[4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 805249-08-5 (6-{[4'-(benzyloxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid 
• 805249-09-6 methyl (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetate 
• 805249-10-9 (6-{[4'-(2-ethoxyethoxy)-2',6'-dimethylbiphenyl-3-yl]methoxy}-2,3-dihydro-1-benzofuran-3-yl)acetic acid 

Relevant articles and documents

Compound with glucose-reducing and lipid-regulating effects as well as preparation and application thereof

The invention discloses a compound with glucose-reducing and lipid-regulating effects as well as a preparation and application thereof. The compound with glucose-reducing and lipid-regulating effectsis a compound with structures as shown in a formula I and a formula II and a pharmaceutically acceptable salt, wherein the structures as shown in the formula I and the formula II are specifically shown in the specification. The preparation is a tablet, a capsule, powder, a pill or an injection prepared by adding pharmaceutically acceptable auxiliary materials into the compound with the glucose-reducing and lipid-regulating effects. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparing an FFA1/PPARdelta dual agonist. The application is the application of the compound with the glucose-reducing and lipid-regulating effects in preparation of drugs for preventing and/or treating glucose metabolic disorder and/or lipid metabolic disorder diseases. The compound and the medicinal salt thereof can be potentially used for treating or preventing diabetes, hyperlipidemia, fatty liver and other related metabolic syndromes, and have wide development prospects.

Novel oxime ether derivative and preparation method thereof and application of derivative by serving as drug

The invention relates to a novel oxime ether derivative shown as a general formula (I) (please see the formula in the description) and a preparation method thereof and application of a pharmaceutical composition containing the derivative in preparation of a drug for treating diabetes and a metabolic syndrome. The oxime ether derivative has the excellent in-vivo hypoglycemic activity and can be used for preventing or treating the diabetes.

Aromatic polycyclic carboxylic acid derivatives

The invention belongs to the field of medicine technology, and specifically relates to an aromatic polycyclic carboxylic acid derivative GPR40 receptor agonist with a general formula (I), a pharmaceutically acceptable salt thereof, and an ester or stereoi